Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 488

1.

Specific targeting of the F13L protein by ST-246 affects orthopoxvirus production differently.

Duraffour S, Vigne S, Vermeire K, Garcel A, Vanstreels E, Daelemans D, Yang G, Jordan R, Hruby DE, Crance JM, Garin D, Andrei G, Snoeck R.

Antivir Ther. 2008;13(8):977-90.

PMID:
19195323
2.

Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures.

Duraffour S, Snoeck R, de Vos R, van Den Oord JJ, Crance JM, Garin D, Hruby DE, Jordan R, De Clercq E, Andrei G.

Antivir Ther. 2007;12(8):1205-16.

PMID:
18240860
3.

ST-246 is a key antiviral to inhibit the viral F13L phospholipase, one of the essential proteins for orthopoxvirus wrapping.

Duraffour S, Lorenzo MM, Zöller G, Topalis D, Grosenbach D, Hruby DE, Andrei G, Blasco R, Meyer H, Snoeck R.

J Antimicrob Chemother. 2015 May;70(5):1367-80. doi: 10.1093/jac/dku545. Epub 2015 Jan 27.

PMID:
25630650
4.

An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge.

Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, Rippen S, Barone L, Burns C, Rhodes G, Tohan S, Huggins JW, Baker RO, Buller RL, Touchette E, Waller K, Schriewer J, Neyts J, DeClercq E, Jones K, Hruby D, Jordan R.

J Virol. 2005 Oct;79(20):13139-49.

5.

Specific inhibition of orthopoxvirus replication by a small interfering RNA targeting the D5R gene.

Vigne S, Germi R, Duraffour S, Larrat S, Andrei G, Snoeck R, Garin D, Crance JM.

Antivir Ther. 2008;13(3):357-68.

PMID:
18572748
6.

Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.

Quenelle DC, Prichard MN, Keith KA, Hruby DE, Jordan R, Painter GR, Robertson A, Kern ER.

Antimicrob Agents Chemother. 2007 Nov;51(11):4118-24. Epub 2007 Aug 27.

7.

Cell line dependency for antiviral activity and in vivo efficacy of N-methanocarbathymidine against orthopoxvirus infections in mice.

Smee DF, Wandersee MK, Bailey KW, Wong MH, Chu CK, Gadthula S, Sidwell RW.

Antiviral Res. 2007 Jan;73(1):69-77. Epub 2006 May 5.

PMID:
16712967
8.

Increased susceptibility of Cantagalo virus to the antiviral effect of ST-246®.

Santos-Fernandes É, Beltrame CO, Byrd CM, Cardwell KB, Schnellrath LC, Medaglia ML, Hruby DE, Jordan R, Damaso CR.

Antiviral Res. 2013 Mar;97(3):301-11. doi: 10.1016/j.antiviral.2012.11.010. Epub 2012 Dec 17.

9.

In vitro activity of cycloSal-nucleoside monophosphates and polyhydroxycarboxylates against orthopoxviruses.

Sauerbrei A, Meier C, Meerbach A, Schiel M, Helbig B, Wutzler P.

Antiviral Res. 2005 Sep;67(3):147-54.

PMID:
16076502
10.

Inhibitors of the lipoxygenase pathway specifically block orthopoxvirus replication.

Palumbo GJ, Buller RM.

Virology. 1991 Jan;180(1):457-63.

PMID:
1898625
11.

Combinatorial optimization of isatin-beta-thiosemicarbazones as anti-poxvirus agents.

Pirrung MC, Pansare SV, Sarma KD, Keith KA, Kern ER.

J Med Chem. 2005 Apr 21;48(8):3045-50.

PMID:
15828843
12.

ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.

Berhanu A, King DS, Mosier S, Jordan R, Jones KF, Hruby DE, Grosenbach DW.

Antimicrob Agents Chemother. 2009 Dec;53(12):4999-5009. doi: 10.1128/AAC.00678-09. Epub 2009 Sep 14.

13.

Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses.

Smee DF, Sidwell RW, Kefauver D, Bray M, Huggins JW.

Antimicrob Agents Chemother. 2002 May;46(5):1329-35.

15.

Screening for vaccinia virus egress inhibitors: separation of IMV, IEV, and EEV.

Byrd CM, Hruby DE.

Methods Mol Biol. 2012;890:113-21. doi: 10.1007/978-1-61779-876-4_6.

PMID:
22688763
17.
18.

siRNA targeting vaccinia virus double-stranded RNA binding protein [E3L] exerts potent antiviral effects.

Dave RS, McGettigan JP, Qureshi T, Schnell MJ, Nunnari G, Pomerantz RJ.

Virology. 2006 May 10;348(2):489-97. Epub 2006 Feb 9.

20.

Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir.

Quenelle DC, Collins DJ, Kern ER.

Antiviral Res. 2004 Jul;63(1):33-40.

PMID:
15196818

Supplemental Content

Support Center